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catabolic factors inﬂuenced the expressions of Ogg1 and 8-oxoguanine
in OA chondrocytes and analysed the relationships among cellular
functions, apoptosis and Ogg1 or 8-oxoguanine expression in human
chondrocytes.
Results: Increased levels of 8-oxoguanine and decreased levels of Ogg1
were observed in OA chondrocytes compared with normal chon-
drocytes in OA rabbits as well as patients with OA. Decreased expression
of Ogg1, but increased expression of 8-oxoguanine, were observed in
chondrocytes treated with OA-related catabolic factors. Ogg1 silencing
using short hairpin RNAs reduced the chondrocyte activity and
augmented chondrocyte apoptosis.
Conclusions: Accumulation of 8-oxoguanine, an oxidized form of
guanine, and downregulation of its repair enzyme Ogg1 in degenerated
articular cartilage may be involved in the pathogenesis of OA. Our
ﬁndings suggest that Ogg1 protects against catabolic stress-induced
chondrocyte dysfunction and apoptosis in OA.Ă
Ă
Fig. 3. Ex vivo experiment. Organ culture of tibiae of mouse embryo (E17.5).Ă
Fig.4. In vivo experiment using Rat OA model. Intraarticular administalation of
DrugX.204
DRUG SCREENING FOR TREATING OSTEOARTHRITIS THROUGH
REGULATION OF WNT SIGNALING
A. Takamatsu y, B. Ohkawara z, T. Sakai y, K. Ohno z,
N. Ishiguro y. yOrthopaedic Surgery, Nagoya Univ. Graduate Schoool of
Med., Nagoya, Japan; zNeurogenetics and Bioinfomatics, Nagoya Univ.
Graduate Schoool of Med., Nagoya, Japan
Purpose: The purposes of this study is to establish a novel therapeutic
strategy for treating osteoarthritis(OA) through regulation of Wnt/b-
catenin signaling.
Methods: Promoter assay: We used a cell-based promoter assay to
screen for chemical activator of FRZB, a soluble antagonist of the Wnt
signaling pathway. This assay utilized Human chondrosarcoma cell co-
transfected with ﬁreﬂy luciferase reporter vector including FRZB
promoter region and Renilla luciferase control vector. We performed
dual screening by combination with TOPFLASH reporter vector that
measures activation of Wnt/b-catenin signaling to ﬁnd drugs activating
FRZB and inhibiting Wnt/b-catenin signaling.
Quantitative RT-PCR & Western blotting: Human articular cartilage
(HAC) was obtained from patients who underwent joint replacement
for knee OA, samples were incubated with DrugX. We quantiﬁed mRNA
levels of chodrogenic markers using realtime RT-PCR and evaluated
protein level of b-catenin by western blotting.
Alcian blue staining: Chondrogenically differentiated ATDC5 were
treated with Wnt3A alone or in the presence of DrugX. After staining
with Alcian blue, the optical density of the extracted dye was measured
using spectrometer.
Organ culture:Mouse embryonic tibiae were cultured with drugX. The
tibial proximal growth plates were either stained with HE and alcian
blue or immunostained with b-catenin antibody.
In vivo surgery and histologic evaluation of OA: We performed rat
DMM surgery for OA model and DrugX was administrated intra-
articularly in right knee. Contralateral kneewas sham-operated. Sagittal
sections were stained with SafraninO and fastgreen and analyzed using
Modiﬁed Mankin Score. Results
We identiﬁed that drugX activated FRZB promoter and inhibitedWnt/b-
catenin signaling in HAC (Fig.1)
Quantitative RT-PCR analyses demonstrated that DrugX upregulated
mRNA levels of FRZB and AGCN, Col2a1, SOX9 dose-dependently, and
inhibited Wnt3A-induced AXIN2 expression (Fig.2)
Western blotting revealed that DrugX decreased the amount of b-cat-
enin protein dose-dependently in HAC (Fig.2)
Alcian Blue staining showed DrugX rescued Wnt3A-inhibited staining
in differentiated ATDC5 (data not shown).Histological analysis of mouse
embryo showed that DrugX diminished the number of hypertrophic
chondrocytes in growth plate. Immunoﬂuoroscene with b-catenin
antibody revealed that DrugX inhibited accumulations of b-catenin in
growth plate (Fig.3).
Analysis of rat OA model showed that DrugX treatment reduced 36% of
cartilage degradation score comparing to that with vehicle treatment at
8 weeks after OA-induced (Fig.4).
Conclusions: We found that DrugX is a novel inhibitor of Wnt/b-cat-
enin signaling in human chondrocytes. Our ﬁndings may open new
avenues for therapeutic intervention in OA.
